# A Phase III Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma

> **NCT00105443** · PHASE3 · COMPLETED · sponsor: **Bayer** · enrollment: 602 (actual)

## Conditions studied

- Carcinoma, Hepatocellular

## Interventions

- **DRUG:** Sorafenib (Nexavar, BAY43-9006)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00105443
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-03
- **Primary completion:** 2008-11
- **Final completion:** 2008-11
- **Target enrollment:** 602 (ACTUAL)
- **Last updated:** 2014-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00105443

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00105443, "A Phase III Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00105443. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*